Dana-farber-cancer Institute Inc.

Vicam L.p.

David M Livingston

William G Kaelin

Thomas L Benjamin

Andrew L Kung

Mark E Ewen

William R Sellers

Steven R Tannenbaum

Gerald N Wogan

Barbara Jackson

Barbara Kohn

Thomsen J Hansen

Joan Chen-Wu

Erik Flemington

Christopher J Basker

Tae-You Kim

Susan George

Daniel Silver

Shoumo Bhattacharya

Ronny Drapkin

Richard Eckner

James A DeCaprio

Christian Bowman-colin

Laura C Wong

Shweta Kitchloo

Joyce Liu

Nucleic acids comprising multifunctional double-stranded break reporter constructs for stable or transient transfection into a cell, as well as detecting a type of double-stranded break repair mechanism in a cell. Methods for detecting types of double-stranded break repair mechanism in a cell, as well as vectors and cells comprising nucleic acids comprising multifunctional double-stranded break reporter constructs.

Multifunctional nucleic acid reporter constructs

The present invention provides methods of detecting ovarian cancer using biomarkers.

Methods of detecting ovarian cancer

Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is 'turned on' only under such conditions.

Light-emitting fusion proteins and diagnostic and therapeutic methods therefor

The invention relates to compositions containing a polynucleotide encoding for a reporter gene, a selectable marker and a regulatory element, that provide a method for imaging cells in vivo.

Composition and method for imaging cells

Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor

The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.

Identification of compounds that modify transcriptional responses to hypoxia

Nucleic acid molecules comprising at least a first signal site and a recombinase gene operably linked to an expression control sequence, such that upon entry into a cell, there is a first signal site and a second signal site positioned to mediate excision of a sufficient portion of either the recombinase gene or the expression control sequence to extinguish recombinase activity when the first and second signal sites are contacted with a recombinase, cells, transgenics and uses of the foregoing.

Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same

A method for increasing the percentage of mammalian offspring of either sex which comprises contacting a semen sample with an antibody specific for the spermatozoa determinative of one sex and separating said spermatozoa from spermatozoa determinative of the other sex, said antibody being bound to a non-porous magnetic bead support having a diameter of 0.1 to 2 microns.

Method for sex determination of mammalian offspring

We have discovered a nuclear protein in normal human cells, 'retinoblastoma-associated protein 1' ('RBAP-1') that binds directly to the retinoblastoma protein pocket of the underphosphorylated form of the retinoblastoma protein ('RB') and does not bind to phosphorylated RB or to RB with inactivating mutations. The translated RBAP-1 sequence does not resemble other proteins whose sequences are known, and RBAP-1 does not contain a sequence homologous to the transforming element common to viral proteins that bind to the RB pocket. RBAP-1 and the E2F transcription activity have similar DNA-binding specificities and can bind to at least some of the same proteins, such as RB and E4.

Retinoblastoma-associated protein 1 CDNA

A cDNA encodes p107; a cell contains recombinant p107-encoding DNA; and substantially all of the cells of a nonhuman mammal contain recombinant p107-encoding DNA. Also, a method for diagnosing a condition of tumorigenicity in a subject, includes the steps of obtaining a tissue sample from the subject and detecting the presence of non wild-type p107-encoding gene in the sample, or detecting the absence of wild-type p107-encoding gene in the sample; or extracting DNA from the sample and detecting the presence of non wild-type p107-encoding gene or the absence of wild-type p107-encoding gene in the DNA. Also, a nucleic acid probe is complementary to a portion of a human mutant p107 gene.

DNA encoding p107 tumor suppressor and related polypeptides

We have discovered a nuclear protein in normal human cells, 'retinoblastoma-associated protein 1' ('RBAP-1'), also known as E2F-1, that binds directly to the retinoblastoma protein pocket of the underphosphorylated form of the retinoblastoma protein ('RB') and does not bind to phosphorylated RB or to RB with inactivating mutations. The translated RBAP-1 sequence does not resemble other proteins whose sequences are known, and RBAP-1 does not contain a sequence homologous to the transforming element common to viral proteins that bind to the RB pocket. RBAP-1 and the E2F transcription activity have similar DNA-binding specificities and can bind to at least some of the same proteins, such as RB and E4.

Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and

An assay method is provided to easily and quickly detect the presence of organisms capable of being cultured, such as bacteria, characterized by antibody capture of the organism of interest by use of specialized magnetic beads, incubation of the captured cells to form colonies; removal of material from the colonies with a colony lift membrane; and detection of the colony material on the membrane sheet by use of labeled antibodies, PCR or nucleic acid probes.

Assay method for detecting presence of bacteria

The invention features an isolated nucleic acid hybridizable with the complement of the coding strand nucleic acid sequence presented in SEQ ID NO:1, and encoding a protein that is necessary for adenovirus transformation of a mammalian cell. The encoded protein, p300, cooperates with adenovirus E1A (Early-region 1A) proteins to establish the transformed state.

Growing community of inventors

Brookline, MA, United States of America

David M Livingston